

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST DECEMBER, 2005**

(Rs. lakhs)

Unaudited				Audited	
9 months ended 30.09.2005	3 months ended 31.12.2005	3 months ended 31.12.2004		Year ended 31.12.2005	Year ended 31.12.2004
123284	34305	30019	Sales	157589	147959
7096	1963	1766	Less: Excise Duty on Sales	9059	10370
116188	32342	28253	Net Sales	148530	137589
2852	1367	831	Other Income	4219	2666
1615	730	840	Interest Income (net)	2345	2668
120655	34439	29924	Total Income	155094	142923
1525	(1471)	(1012)	Materials Consumed (Increase) / decrease in stock-in-trade	54	(318)
47748	14844	12664	Consumption of raw and packing materials and purchase of finished goods	62592	59404
49273	13373	11652	Total Materials Consumed	62646	59086
924	568	720	Excise Duty on Samples and (Increase) / Decrease in Stock-in-Trade	1492	1241
11526	4022	3072	Staff Cost	15548	14397
18945	8140	7215	Other Expenditure	27085	25578
(654)	(387)	(436)	Recovery of Expenses	(1041)	(950)
80014	25716	22223	Total Expenditure	105730	99352
1132	441	514	Depreciation	1573	1747
39509	8282	7187	Profit before Tax and Exceptional Items	47791	41824
12832	2696	2062	Provision for Taxation - Current tax (including fringe benefit tax)	15528	13964
1173	462	732	- Deferred tax	1635	1255
25504	5124	4393	Net Profit after Tax before Exceptional Items	30628	26605
20466	(886)	(2030)	Exceptional Items (net of tax)	19580	6704
45970	4238	2363	Net Profit	50208	33309
8470	8470	8732	Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8732
			Reserves excluding Revaluation Reserves	86390	83694
29.6	6.0	5.0	Earnings per Share before Exceptional Items (Rs.)	35.7	30.5
53.3	5.0	2.7	Earnings per Share / Diluted Earnings per Share (Rs.)	58.5	38.1
			Aggregate of Non-promoter Shareholding :		
41785529	41785529	44405058	Number of Shares	41785529	44405058
49.3%	49.3%	50.9%	% of Shareholding	49.3%	50.9%

- The Company registered a sales growth of 14.5% during the quarter ended 31st December, 2005. The strong sales performance during the last three quarters of this year has more than offset the sales decline in the first quarter, resulting in a growth of 8% for the year from the Pharmaceuticals and the other businesses of the Company. Profit after Tax and before Exceptional Items grew by 15.1% over the previous year.
- Exceptional Items for the year ended 31st December, 2005 are mainly in respect of profit on sale of two properties located at Mulund, Mumbai less expenses connected therewith, provision for pricing of formulations and costs associated with buy back of shares.
- Pursuant to the buy back announcement made by the Company on 30th April, 2005, the Company has bought back from the open market through stock exchanges and extinguished 2619529 shares during year ended 31st December, 2005. Consequent to the buy back, the paid-up equity share capital as on 31st December, 2005 is Rs. 8470.30 lakhs and the promoter shareholding is 50.7%.
- Earnings per share has been calculated based on weighted average number of equity shares after adjusting the number of shares bought back and extinguished.
- There were no Investor complaints pending as at the beginning of the quarter. The Company has received 4 complaints from the investors during the quarter and all of them have since been resolved, leaving no investor complaints unresolved at the end of the quarter.
- The Board of Directors recommends a Dividend of Rs. 14 per equity share (Previous year Rs. 13 per equity share) and a special additional one-time Dividend of Rs. 14 per equity share (Previous year Rs. 11 per equity share).
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th February, 2006. The figures for 2004 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

13th February, 2006

S. Kalyanasundaram
Managing Director